The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors

På svenska

Author

  • Helge R. Brekke
  • Matthias Kolberg
  • Rolf I. Skotheim
  • Kirsten S. Hall
  • Bodil Bjerkehagen
  • Bjorn Risberg
  • Henryk Domanski
  • Nils Mandahl
  • Knut Liestol
  • Sigbjorn Smeland
  • Havard E. Danielsen
  • Fredrik Mertens
  • Ragnhild A. Lothe
Show all

Summary, in English

The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment. Neuro-Oncology 11, 514-528, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00271, January 30, 2009.)

Publishing year

2009

Language

English

Pages

514-528

Publication/Series

Neuro-Oncology

Volume

11

Issue

5

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Cancer and Oncology

Keywords

  • neurofibroma
  • cyclin D1
  • MPNST
  • NF1
  • p53

Status

Published

ISBN/ISSN/Other

  • ISSN: 1523-5866